A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TER
JG Whisenant , J Baena , A Cortellini , L-C Huang
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
2022
P1. 08D. 03 Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-Small Cell Lung Cancer (NSCLC)
RE Sanborn , D Hanes , D Shaker , MJ Fidler
Journal of Thoracic Oncology 19 ( 10) S184 -S184
2024
Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
Greg Andrew Durm , Hirva Mamdani , Sandra K Althouse , Salma K Jabbour
Journal of Clinical Oncology 40 ( 16_suppl) 8509 -8509
17
2022
Sexual dysfunction in women with lung cancer: Updates from the SHAWL study.
Narjust Florez , Lauren Kiel , Kelly Meza , Zihan Wei
Journal of Clinical Oncology 41 ( 16_suppl) 9071 -9071
4
2023
Paired tumor/normal sequencing to overcome racial differences in tumor mutational burden (TMB).
Kenneth Robert Carson , Ameen Salahudeen , Mary Jo J Fidler , Christopher W Seder
Journal of Clinical Oncology 40 ( 16_suppl) 3138 -3138
1
2022
RNA sequencing to characterize pathways in EGFR-mutated non-small cell lung cancer.
Nicole Yun , Ankur D Naqib , Jeffrey Allen Borgia , Marta Batus
Journal of Clinical Oncology 41 ( 16_suppl) e21019 -e21019
2023
Clinical outcomes in patients with radioiodine refractory thyroid carcinoma treated with dose-reduced lenvatinib.
Cherry Au , Brian Kim , Mary Jo J Fidler , Michael J Jelinek
Journal of Clinical Oncology 41 ( 16_suppl) e18104 -e18104
2023
Gender and weight change, skeletal muscle index (SMI) change, and survival in advanced non-small cell lung cancer (NSCLC) patients (pts.) receiving platinum chemotherapy.
Mary Jo J Fidler , Palmi Shah , Hita Moudgalya , Marta Batus
Journal of Clinical Oncology 40 ( 16_suppl) e24080 -e24080
2022
Clinical and laboratory parameters associated with rapid progression in advanced NSCLC patients treated with second or third-line single agent immune checkpoint inhibitors (ICIs).
Megan Randall , Philip D Bonomi , Sanjib Basu , Jeffrey Allen Borgia
Journal of Clinical Oncology 40 ( 16_suppl) e21087 -e21087
2022
CX-2009, a CD166-directed PROBODY drug conjugate (PDC): results from the first-in-human study in patients with advanced cancer including breast cancer
Valentina Boni , Howard Burris , Joyce Liu , Alexander Spira
Breast cancer 42 44 -44
1
2020
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
Marta Batus , Lela Buckingham , John Coon , Mary Jo Fidler
Anticancer Research 32 ( 5) 1705 -1710
17
2012
Treatment of locally advanced non-small cell lung cancer.
Mary Jo Fidler , Philip Bonomi , Anthony W. Kim , Thomas Zusag
Clinical advances in hematology & oncology 7 ( 7) 455
5
2009
Practice-Changing Findings.
Mary Jo Fidler
Oncology 29 ( 7) 502
2015
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Marta Batus , Imad Tarhoni , Jeffrey A. Borgia , Mary Jo Fidler
Journal of Immunological Methods 490 112956
2021
Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy.
Marta Batus , Imad Tarhoni , Jeffrey A Borgia , Mary Jo Fidler
Cancers 13 ( 6) 1426
2021
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
Marta Batus , Mary Jo Fidler , Philip D Bonomi
Expert Review of Anticancer Therapy 10 ( 10) 1589 -1599
5
2010
National patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma
David J. Sher , Chad G. Rusthoven , Saad A. Khan , Mary Jo Fidler
Cancer 123 ( 2) 273 -282
14
2017
Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base
David J. Sher , Matthew Koshy , Michael J. Liptay , Mary Jo Fidler
Cancer 120 ( 13) 2060 -2068
31
2014
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra EW Cohen , Denis Soulières , Christophe Le Tourneau , José Dinis
The Lancet 393 ( 10167) 156 -167
1,036
2019
Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy
Mary Jo Fidler , Casey Frankenberger , Richard Seto , Gabriela C Lobato
Oncotarget 8 ( 35) 58108 -58121
6
2017